Clinical trials: B-cell Neoplasm
Chronic Lymphocytic Leukemia
Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the first line therapy of chronic lymphocytic leukemia
- Trial name
- NORMA (NCT02110394)
- Testing
- bendamustine, rituximab
- Where
- 34 sites in Russia
- Volunteers
- 190 people
- Sponsor
- Astellas Pharma Europe B.V.
Relapsed/Refractory Large B Cell Lymphoma
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to…
- Trial name
- EXPAND (NCT05714345)
- Testing
- ALLO-647, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States, Belgium
- Volunteers
- 2 people
- Sponsor
- Allogene Therapeutics
Multiple Myeloma
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants…
- Trial name
- DREAMM 8 (NCT06956170)
- Testing
- Belantamab mafodotin, Pomalidomide, Dexamethasone
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma, Multiple Myeloma in Relapse
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Mantle Cell Lymphoma in Relapse, Diffuse Large B Cell Lymphoma in Relapse
- Trial name
- NCT01435720
- Testing
- SNS01-T
- Where
- 7 sites in United States, South Africa
- Volunteers
- 15 people
- Sponsor
- Senesco Technologies, Inc.
Lymphoma, Chronic Lymphocytic Leukemia
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.
- Conditions
- Lymphoma, Chronic Lymphocytic Leukemia, Solid Tumors
- Trial name
- NCT01021358
- Testing
- ABT-263, Ketoconazole
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abbott
Lymphoma, B-Cell
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
The goal of this clinical research study is to find out if the study drug, ONTAK (denileukin diftitox), can shrink or slow the growth of B-cell non-Hodgkin's lymphoma (NHL) in patients whose disease has not responded to prior…
- Trial name
- NCT00211276
- Testing
- ONTAK (denileukin diftitox)
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eisai Inc.
B-cell Malignancy
Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART22 (Allogeneic CAR-T targeting CD22) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).
- Trial name
- NCT05106946
- Testing
- ThisCART22 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fundamenta Therapeutics, Ltd.
Lymphoma, B-Cell
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas.
- Trial name
- NCT06792734
- Testing
- BTM-3566
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Bantam Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
This study is designed to assess the safety, pharmacokinetics, drug-drug interactions, and determine the recommended Phase 2 doses of co administered Duvelisib and Venetoclax in participants with relapsed or refractory chronic…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT02640833
- Testing
- Duvelisib, Venetoclax
- Where
- 10 sites in United States
- Sponsor
- AbbVie
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
Lymphoma
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00258336
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, rituximab, sargramostim
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Favrille
Non-Hodgkin Lymphoma, Follicular Lymphoma
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage, a combination stage, and a randomized dose-expansion stage…
- Conditions
- Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL, Mantle Cell Lymphoma
- Trial name
- NCT04082936
- Testing
- imvotamab
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 97 people
- Sponsor
- IGM Biosciences, Inc.
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
This is an open label clinical study: Phase Ia is a dose escalation phase, evaluating the safety, tolerability, RP2D, PK characteristics, and preliminary efficacy of IBR900 cell injection in the treatment of relapsed/refractory…
- Trial name
- NCT07073833
- Testing
- IBR900 cell injection, rituximab
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Imbioray (Hangzhou) Biomedicine Co., Ltd.
Chronic Lymphocytic Leukemia
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.
- Trial name
- NCT02100852
- Testing
- TGR-1202 + Obinutuzumab + Chlorambucil
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- TG Therapeutics, Inc.
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma.
- Trial name
- NCT07124936
- Testing
- HDM2005, Rituximab or Rituximab biosimilar, Gemcitabine
- Where
- 21 sites in China
- Volunteers
- 97 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diffuse Large B-Cell Lymphoma
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
This is a randomized, open-label, active-control, parallel-group, multicenter, multinational Phase 2 Study of the efficacy and safety of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab…
- Trial name
- NCT01040871
- Testing
- VELCADE, Rituximab, Cyclophosphamide
- Where
- Belgium
- Volunteers
- 164 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
The treatment combination of Rituxan® (rituximab) and fludarabine has previously been reported to produce a high percentage of responses with less toxicity than other combination treatments.
- Trial name
- NCT00078234
- Testing
- Oblimersen-rituximab-fludarabine
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genta Incorporated
Select Relapsed/Refractory Lymphoid Malignancies
A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies.
- Trial name
- VIJAY-1 (NCT06761586)
- Testing
- AUR104
- Where
- 5 sites in India
- Volunteers
- 9 people
- Sponsor
- Aurigene Discovery Technologies Limited
Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
ZX-101A-101 is a Phase 1/2a, first-in-human, open-label, multicenter, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary antitumor activity of ZX-101A…
- Conditions
- Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT04504708
- Testing
- ZX-101A
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Hangzhou Zenshine Pharmaceuticals Co., Ltd.
Chronic Lymphocytic Leukemia
A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia
This phase II trial was designed to evaluate the efficacy of obinutuzumab and bendamustine treatment in participants with refractory or relapsed chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02071225
- Testing
- bendamustine, obinutuzumab
- Where
- 21 sites in Spain
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche